

NEW ZEALAND DATA SHEET

WARNING: SERIOUS MENINGOCOCCAL INFECTION

Soliris® increases the risk of meningococcal infections

- Vaccinate patients against meningococcal infection (*Neisseria meningitides*) at least 2 weeks prior to receiving Soliris, unless the risk of delaying Soliris therapy outweighs the risk of meningococcal infection.
- Vaccinate and/or revaccinate according to current national vaccination guidelines; vaccines against serogroups A, B, C, Y and W135 are recommended.
- Patients who initiate Soliris treatment less than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination.
- Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

1. PRODUCT NAME

Soliris® 300mg/30mL solution for infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains 10mg/mL (300mg/30mL) eculizumab.

Eculizumab is a genetically-engineered humanised monoclonal antibody produced from murine myeloma cells.

Excipients with known effect: sodium chloride (5 mmol).

For the full list of excipients, see section 6.1 List of Excipients.

3. PHARMACEUTICAL FORM

Solution for infusion.

Sterile, clear, colourless, preservative-free solution in glass vials. The product is formulated at pH 7.0.

4. CLINICAL PARTICULARS

4.1 Therapeutic Indications

Soliris is indicated for the treatment of patients with:

- Paroxysmal Nocturnal Haemoglobinuria (PNH) to reduce haemolysis.
- atypical Haemolytic Uraemic Syndrome (aHUS)

NEW ZEALAND DATA SHEET

4.2 Dose and Method of Administration

Dosage Regimen

Patients must be administered a meningococcal vaccine at least two weeks prior to receiving Soliris therapy. Refer to Box Warning and Section 4.4 – Special Warnings and Precautions for Use; Meningococcal Infection and Immunisation, for vaccination information before initiating Soliris treatment.

Soliris should be administered by a healthcare professional and under appropriate medical supervision.

Adult Patients

Paroxysmal Nocturnal Haemoglobinuria (PNH)

The PNH dosing regimen for adult patients (≥ 18 years of age) consists of a 4 week initial phase followed by a maintenance phase:

- Initial phase: 600 mg of Soliris administered via a 25 - 45 minute intravenous infusion every week for the first 4 weeks
- Maintenance phase: 900 mg of Soliris administered via a 25 - 45 minute intravenous infusion on the fifth week, followed by 900 mg of Soliris administered via a 25 -45 minute intravenous infusion every 14 ± 2 days.

atypical Haemolytic Uraemic Syndrome (aHUS)

The aHUS dosing regimen for adults (≥ 18 years of age) consists of a 4 week initial phase followed by a maintenance phase:

- Initial phase: 900 mg of Soliris via a 25 - 45 minute intravenous infusion every week for the first 4 weeks
- Maintenance phase: 1200 mg of Soliris administered via a 25 - 45 minute intravenous infusion on the fifth week, followed by 1200 mg of Soliris administered via a 25 -45 minute intravenous infusion every 14 ± 2 days.

Paediatric patients (< 18 years of age)

Paediatric PNH and aHUS patients with body weight ≥ 40 kg are treated with the adult dosing recommendations above.

For paediatric PNH and aHUS patients with body weight below 40 kg, the Soliris dosing regimen consists of:

Patient Body Weight*	Initial Phase	Maintenance Phase
30 to <40 kg	600 mg on weeks 1 and 2	900 mg on week 3; then 900 mg every 2 weeks
20 to <30 kg	600 mg on weeks 1 and 2	600 mg at week 3; then 600 mg every 2 weeks
10 to <20 kg	600 mg on week 1	300 mg on week 2; then 300 mg every 2 weeks
5 to <10 kg	300 mg on week 1	300 mg on week 2; then 300 mg every 3 weeks

*Soliris has not been studied in patients with PNH who weigh <40kg. The dosing for PNH patients <40kg weight is based on the dosing used for patients with aHUS and who weigh <40kg.

NEW ZEALAND DATA SHEET

Treatment Monitoring/Dose Modifications

Patients with PNH may need to be monitored to determine whether the 14 day dosing schedule needs to be reduced to 12 days (refer to section 4.4 Special Warnings and Precautions for Use).

aHUS patients should be monitored for signs and symptoms of thrombotic microangiopathy (TMA) (refer to section 4.4–Special Warnings and Precautions for Use).

Soliris treatment is recommended to continue for the patient’s lifetime, unless the discontinuation of Soliris is clinically indicated.

Soliris should be administered at the recommended dosage regimen time points, or within 2 days of these time points. If a patient misses a scheduled dose, monitor for signs and symptoms of a TMA complication (refer to Section 4.4 – Special Warnings and Precautions for Use; Laboratory Monitoring) and resume the regular schedule as soon as possible. If a patient misses multiple doses of Soliris re-induction can be considered. Supplemental dosing of Soliris is required in the setting of concomitant Plasma intervention (plasmapheresis or plasma exchange, or plasma infusion) as follows:

Type of Plasma Intervention	Most Recent Soliris Dose	Supplemental Soliris Dose with Each Plasma Intervention	Timing of Supplemental Dose
Plasmapheresis or plasma exchange	300 mg	300 mg per each plasmapheresis or plasma exchange session	Within 60 minutes after each plasmapheresis or plasma exchange session
	≥600 mg	600 mg per each plasmapheresis or plasma exchange session	
Plasma infusion	≥300 mg	300 mg per plasma infusion session	60 minutes prior to each plasma infusion session

Administration

Do Not Administer as an Intravenous Push or Bolus Injection

For instructions on dilution of the product before administration, see section 6.6 Special Precautions for Disposal and other Handling.

The Soliris admixture should be administered by intravenous infusion over 25 - 45 minutes in adults, and 1 to 4 hours in paediatric patients, via gravity feed, a syringe-type pump or an infusion pump. It is not necessary to protect the diluted solution of Soliris from light during administration to the patient.

If an adverse event occurs during the administration of Soliris, the infusion may be slowed or stopped at the discretion of the physician. If the infusion is slowed, the total infusion time should not exceed 2 hours in adults and adolescents and 4 hours in children aged less than 12 years of age.

Monitor the patient for at least 1 hour following completion of the infusion for signs or symptoms of an infusion reaction.

Paediatric Population: The route of administration of Soliris is the same for all age groups.

Elderly: Soliris may be administered to patients aged 65 years and over. There is no evidence to suggest that any special precautions are needed when older people are treated – although experience with Soliris in this patient population is still limited.

Renal impairment: No dose adjustment is required for patients with renal impairment.

Hepatic impairment: The safety and efficacy of Soliris have not been studied in patients with hepatic impairment.

NEW ZEALAND DATA SHEET

4.3 Contraindications

Hypersensitivity to eculizumab; murine proteins; or to any of the excipients listed in Section 6.1.

Do not initiate Soliris therapy in patients:

- with unresolved *Neisseria meningitidis* infection.
- who are not currently vaccinated against *Neisseria meningitidis* (unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination).

4.4 Special Warnings and Precautions for Use

Serious Infections

Serious Meningococcal Infections

Due to its mechanism of action, the use of Soliris increases a patient's susceptibility to meningococcal infection (*Neisseria meningitides*). Meningococcal infection due to any serogroup may occur. To reduce the risk of infection, all patients must be vaccinated at least 2 weeks prior to receiving Soliris, unless the risks of delaying Soliris therapy outweigh the risks of developing a meningococcal infection. Patients who initiate Soliris treatment less than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Vaccines against serogroups A, B, C, Y and W135 are recommended in minimising infection with the commonly pathogenic meningococcal serogroups (see Section 4.4-Special Warnings and Precautions for Use; Immunisation). Vaccinate and/or re-vaccinate according to current national vaccination guidelines.

For patients stabilised on Soliris and receiving maintenance therapy, and for whom additional vaccination is warranted, careful consideration should be given to the timing of vaccination relative to administration of Soliris (see Section 4.4 – Special Warnings and Precautions for Use; Immunisation).

Cases of serious or fatal meningococcal infections have been reported in Soliris-treated patients. Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents. All patients must be monitored for early signs of meningococcal infections, evaluated immediately if an infection is suspected, and treated with appropriate antibiotics if necessary. Patients should be informed of these signs and symptoms and steps taken to seek medical care immediately (see Section 4.4 - Special Warnings and Precautions for Use; Educational Materials).

Other Systemic Infections

Due to its mechanism of action, Soliris therapy should be administered with caution to patients with active systemic infections. Soliris blocks terminal complement activation; therefore patients may have increased susceptibility to infections, especially with *Neisseria* and encapsulated bacteria. Serious infections with *Neisseria* species (other than *N. meningitidis*), including disseminated gonococcal infections, have been reported.

Patients should be provided with information from the Patient/Parent Guide to increase their awareness of potential serious infections and their signs and symptoms. Counsel patients about gonorrhoea prevention and advise regular testing for patients at-risk.

NEW ZEALAND DATA SHEET

Infusion Reactions

Administration of Soliris may result in infusion reactions or immunogenicity that could cause allergic or hypersensitivity reactions (including anaphylaxis). Immune system disorders within 48 hours of Soliris administration did not differ from placebo treatment in PNH, aHUS and other studies conducted with Soliris. In clinical trials, no patients with PNH or aHUS experienced an infusion reaction which required discontinuation of Soliris. Soliris administration should be interrupted in all patients experiencing severe infusion reactions and appropriate medical therapy administered.

Immunogenicity

Infrequent, low titre antibody responses have been detected in Soliris-treated patients across all studies. In placebo-controlled studies low titre responses have been reported with a frequency (3.4%) similar to that of placebo (4.8%). In patients with aHUS, treated with Soliris, antibodies to Soliris were detected in 3/100 (3%) by the ECL bridging format assay. 1/100 (1%) of patients with aHUS had low positive values for neutralizing antibodies. There has been no observed correlation of antibody development to clinical response or adverse events.

Immunisation

Patients under 18 years of age must be vaccinated against *Haemophilus influenzae* and *Streptococcus pneumoniae* and strictly need to adhere to the national vaccination recommendations of each age group.

All patients must be vaccinated against meningococcal infection (*Neisseria meningitidis*) at least 2 weeks prior to receiving Soliris, unless the risk of delaying Soliris therapy outweighs the risk of meningococcal infection. Patients who initiate Soliris treatment less than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination (see also Section 4.4 Special Warnings and Precautions for Use). Vaccines against serogroups A, B, C, Y, and W135 are recommended in minimising infection with the commonly pathogenic meningococcal serogroups.

Vaccination may further activate complement. As a result, patients with complement-mediated diseases, including PNH and aHUS, may experience increased signs and symptoms of their underlying disease, such as haemolysis (PNH) or TMA complications (aHUS). Therefore, patients should be closely monitored for disease symptoms after recommended vaccination.

For patients stabilised on Soliris and receiving maintenance therapy, and for whom additional vaccination is warranted, careful consideration should be given to the timing of vaccination (or booster in patients previously vaccinated against meningococcal infections) relative to administration of Soliris.

Patients must be vaccinated and/or re-vaccinated according to current national vaccination guidelines.

Anticoagulant Therapy

The effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established. Treatment with Soliris should not alter anticoagulant management.

NEW ZEALAND DATA SHEET

Laboratory Monitoring

PNH Laboratory monitoring: patients with PNH should be monitored for signs and symptoms of intravascular haemolysis. Patients with PNH receiving Soliris therapy should be monitored for intravascular haemolysis by measuring LDH levels, and may require dose adjustment within the recommended 14+/-2 day dosing schedule during the maintenance phase (up to every 12 days).

aHUS Laboratory monitoring: patients with aHUS receiving Soliris should be monitored for thrombotic microangiopathy by measuring platelet counts, serum LDH levels and serum creatinine and may require dose adjustment within the recommended 14 ± 2 day dosing schedule during the maintenance phase (up to every 12 days).

Monitoring after Soliris Discontinuation

Treatment Discontinuation for PNH

If patients with PNH discontinue treatment with Soliris they should be closely monitored for signs and symptoms of serious intravascular haemolysis. Serious haemolysis is identified by serum LDH levels greater than the pre-treatment level, along with any of the following: greater than 25% absolute decrease in PNH red blood cell clone size (in the absence of dilution due to transfusion) in one week or less; a haemoglobin level of <50 g/L or a decrease of >40 g/L in one week or less; angina; change in mental status; a 50% increase in serum creatinine level; or thrombosis. Monitor any patient who discontinues Soliris for at least 8 weeks to detect serious haemolysis and other reactions.

If serious haemolysis occurs after Soliris discontinuation, consider the following procedures/treatments: blood transfusion (packed RBCs), or exchange transfusion if the PNH RBCs are >50% of the total RBCs by flow cytometry; anticoagulation; corticosteroids; or reinstatement of Soliris. In PNH clinical studies, 16 patients discontinued treatment with Soliris. Serious haemolysis was not observed.

Treatment Discontinuation for aHUS

Severe thrombotic microangiopathy (TMA) complications were observed following Soliris discontinuation in aHUS clinical studies (in some patients up to 127 weeks after discontinuation) and can occur at any time. Discontinuation of treatment is not recommended unless medically justified. Close monitoring of patients with aHUS who discontinue Soliris treatment for signs and symptoms of severe TMA complications should commence immediately after discontinuation.

Severe TMA complications post discontinuation can be identified by;

- i. any two, or repeated measurement of any one of the following: a decrease in platelet count of 25% or more as compared to either baseline or to peak platelet count during Soliris treatment; an increase in serum creatinine of 25% or more as compared to baseline or to nadir during Soliris treatment; or, an increase in serum LDH of 25% or more as compared to baseline or to nadir during Soliris treatment; or
- ii. any one of the following: a change in mental status or seizures; angina or dyspnoea; or thrombosis.

Monitoring may be insufficient to predict or prevent severe TMA complications in patients with aHUS.

If severe TMA complications occur after Soliris discontinuation, consider reinstatement of Soliris treatment, supportive care with PE/PI, or appropriate organ-specific supportive measures including renal support with dialysis, respiratory support with mechanical ventilation or anticoagulation.

NEW ZEALAND DATA SHEET

Sixty one patients (21 paediatric) discontinued Soliris in the aHUS clinical trials (median follow up 24 weeks). Fifteen severe TMA complications were observed in 12 patients following treatment discontinuation, and 2 severe TMA complications occurred in 2 additional patients that received a reduced Soliris dose outside the approved dosing regimen. Severe TMA complications occurred regardless of whether the patient had an identified genetic mutation, high risk polymorphism or auto-antibodies. Additional serious medical complications occurred in these patients, including severe worsening of kidney function, progression to end stage renal disease requiring dialysis and disease-related hospitalisation. Despite Soliris re-initiation following discontinuation, progression to end stage renal disease occurred in 1 patient.

Educational Materials

All physicians who intend to prescribe Soliris must ensure they are familiar with the physician's guide to prescribing. Physicians must discuss the benefits and risks of Soliris therapy with patients and provide them with a Patient/Parent Guide and a Patient Safety Information Card.

Patients should be instructed that if they develop fever, headache accompanied with fever and/or stiff neck or sensitivity to light, they should immediately seek medical care as these signs may be indicative of meningococcal infection.

Patients on Controlled Sodium Diets

Soliris contains 5 mmol sodium per vial. This should be taken into consideration when calculating the sodium intake of patients on a controlled sodium diet.

Paediatric Use

Soliris has not been studied in paediatric patients with PNH who weigh less than 40 kg.

Use in the Elderly

Soliris may be administered to patients aged 65 years and over. There is no evidence to suggest that any special precautions are needed when older people are treated-although experience with Soliris in this patient population is still limited.

4.5 Interaction with Other Medicines and Other Forms of Interaction

Chronic intravenous human immunoglobulin (IVIg) treatment may interfere with the endosomal neonatal Fc receptor (FcRn) recycling mechanism of monoclonal antibodies such as eculizumab, and thereby decrease serum eculizumab concentrations. Drug interaction studies have not been conducted with Soliris in patients treated with IVIg.

Plasmapheresis (PP), Plasma Exchange (PE) and Plasma Infusion (PI) have been shown to reduce SOLIRIS serum levels. A supplemental dose of SOLIRIS is required in these settings. See *Section 4.2 Treatment Monitoring/Dose Modifications* for guidance in case of concomitant PE, PP and PI treatment.

Concomitant use of SOLIRIS with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of SOLIRIS. Closely monitor for reduced effectiveness of SOLIRIS.

NEW ZEALAND DATA SHEET

4.6 Fertility, Pregnancy and Lactation

Pregnancy

Use in Pregnancy - Category B2

There are no well-controlled studies in pregnant women treated with Soliris. Post-market data and literature on a limited number of pregnancies exposed to Soliris (less than 300 pregnancy outcomes) indicate there is no increased risk of fetal malformation or fetal-neonatal toxicity compared to the existing risk in PNH and aHUS; however, due to the lack of well-controlled studies, uncertainties remain. As an IgG antibody, eculizumab is expected to cross the placenta. Animal studies conducted with a surrogate antibody did not reveal obvious teratogenicity but are of limited predictive value. There is not enough data to determine the risks of Soliris use during pregnancy. Use of Soliris in pregnancy should be carefully considered, with regards to the specific risks (including maternal and neonatal death and non-live birth) and benefits for each patient. An individual risk benefit analysis is recommended before starting and during treatment with Soliris in pregnant women. Should treatment be considered necessary during pregnancy, close maternal and fetal monitoring according to local guidelines is recommended.

Soliris should be used during pregnancy only if the potential benefit justifies the potential risk to the mother, fetus and/or neonate. Unless pregnancy is specifically desired, women should use adequate contraception during treatment with Soliris, and for up to 5 months after treatment.

Clinical Considerations

There are risks to the mother and fetus associated with treated and untreated PNH and aHUS. PNH in pregnancy is associated with adverse maternal outcomes, including worsening cytopenias, thrombotic events, infections, bleeding, miscarriages and increased maternal mortality, and adverse fetal outcomes, including fetal death and premature delivery. aHUS in pregnancy is associated with adverse maternal outcomes, including pre-eclampsia and preterm delivery, and adverse fetal/neonatal outcomes, including intrauterine growth restriction (IUGR), fetal death and low birth weight. There is a risk of maternal, fetal or neonatal death with both PNH and aHUS pregnancies whether treated with Soliris or not.

Human Data

Limited data are available from reports of pregnancy-related outcomes from the safety database. Analysis of available data show no difference in the risk of overall major birth defects for Soliris (0.94 per 100 live-births) compared with the background rate for major birth defects of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) or 2-3% in the U.K. reference population. The rate of fetal death (miscarriage and stillbirth) observed in the safety database is estimated to be 16.2%. The estimated background rate of miscarriage in clinically recognised pregnancies in the U.S. general population is 15-20%.

The background risk of birth defects for the indicated population of PNH or aHUS is not thought to be different than that in the general population. Rates of miscarriage and still birth are reported to be as high as 26% and 10% respectively in PNH. Methodological limitations of this data analysis include the use of MACDP and published literature on PNH and aHUS as the external comparator group. The MACDP population is not disease-specific, evaluates women and infants from a limited geographic area, and does not include outcomes for births that occurred at <20 weeks gestation.

NEW ZEALAND DATA SHEET

Animal Data

In reproductive toxicology studies in mice with the murine surrogate terminal complement inhibitory antibody given during the period of organogenesis, there were no clearly treatment-related findings in fetuses of mice exposed to 60 mg/kg/week, a dose comparable to the human dose of Soliris on a mg/kg basis. When maternal exposure to the murine antibody occurred from the time of implantation to the end of lactation, a slightly higher number of male offspring became moribund or died in the group given 60 mg/kg/week. The relevance to use of Soliris is unclear.

Breast-feeding

Although limited published data does not report detectable levels of eculizumab in human milk, maternal IgG is known to be present in human milk. Available information is insufficient to inform the effect of eculizumab on the breastfed infant. There are no data on the effects of eculizumab on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Soliris and any potential adverse effects on the breastfed child from Soliris or from the underlying maternal condition.

Fertility

No studies have been conducted to assess the effects of eculizumab on male and female fertility. In animal studies with a surrogate terminal complement inhibitor (murine anti-C5) antibody, no adverse effects on the fertility of treated mice were observed.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Undesirable Effects

Clinical Trial Experience

PNH

The data described below reflect exposure to Soliris in 196 adult patients with PNH, age 18-85, of whom 55% were female. All had signs or symptoms of intravascular haemolysis. Soliris was studied in a placebo-controlled clinical study (in which 43 patients received Soliris and 44, placebo); a single arm clinical study and a long-term extension study. 182 patients were exposed for greater than one year. All patients received the recommended Soliris dose regimen.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Table 1 summarises the adverse reactions that occurred at a numerically higher rate in the Soliris group than the placebo group and at a rate of 5% or more among patients treated with Soliris.

NEW ZEALAND DATA SHEET

Table 1: Adverse Drug Reactions* reported in ≥2% of patients in the Controlled Clinical Study

Adverse Drug Reaction	Soliris N = 43 (%)	Placebo N = 44 (%)
NERVOUS SYSTEM		
Headache	15 (34.9)	2 (4.5)
GASTROINTESTINAL		
Nausea	2 (4.7)	1 (2.3)
Abdominal pain	2 (4.7)	1 (2.3)
GENERAL		
Fatigue	5 (12)	1 (2)
INFECTIONS AND INFESTATIONS		
Oral Herpes	2 (4.7)	0 (0)
Upper respiratory tract infection	2 (4.7)	0 (0)
SKIN AND SUBCUTANEOUS TISSUE		
Dry skin	2 (4.7)	0 (0)

*Drug-related Adverse Events occurring at a higher frequency (1 or more patients) in the Soliris-treated patients relative to placebo

In the placebo-controlled clinical study, serious adverse reactions occurred among 4 (9%) patients receiving Soliris and 9 (21%) patients receiving placebo. The serious reactions included infections and progression of PNH. No deaths occurred in the study and no patients receiving Soliris experienced a thrombotic event; one thrombotic event occurred in a patient receiving placebo.

Among 193 patients with PNH treated with Soliris in the single arm, clinical study or the follow-up study, the adverse reactions were similar to those reported in the placebo-controlled clinical study. Serious adverse reactions occurred among 16% of the patients in these studies. The most common serious adverse reactions were: viral infection (2%), headache (2%), anaemia (2%), and pyrexia (2%).

Paediatric patients

The safety profile in paediatric patients (aged 11 years to <17 years) with PNH included in the PNH Study *M07-005*, appeared similar to that observed in adult patients with PNH. The most common adverse reaction reported in paediatric patients was headache.

aHUS

The safety of Soliris in patients with aHUS was evaluated in 1 retrospective paediatric study (*C09-001r*) and 4 prospective, single-arm studies [3 in adult patients (*C08-002A/B*, *C08-003A/B* and *C10-004*) and 1 in paediatric patients (*C10-003*)].

The data described below in Table 2 were derived from 78 adult aHUS patients enrolled in Studies *C08-002A/B*, *C08-003A/B* and *C10-004*. Paediatric safety data are summarised in Table 4 and refer to Table 5 for additional safety data collected in 30 patients in the retrospective study *C09-001r*.

NEW ZEALAND DATA SHEET

Table 2: Per Patient Incidence of Adverse Drug Reactions (ADRs) in ≥10% of Adult and Adolescent Patients Enrolled in aHUS studies C08-002A/B, C08-003A/B and C10-004, Separately and in Total

MedDRA SOC	Number (%) of Patients			
	C08-002 (n=17)	C08-003 (n=20)	C10-004 (n=41)	Total (n=78)
Blood and Lymphatic System Disorders				
Leucopaenia	2 (11.8)	2 (10.0)	0 (0.0)	4 (5.1)
Lymphopaenia	0 (0.0)	2 (10.0)	0 (0.0)	2 (2.6)
Gastrointestinal Disorders				
Nausea	2 (11.8)	0 (0.0)	0 (0.0)	2 (2.6)
Vomiting	3 (17.6)	0 (0.0)	1 (2.4)	4 (5.1)
Nervous System Disorders				
Headache	1 (5.9)	3 (15.0)	0 (0.0)	4 (5.1)
Respiratory, Thoracic and Mediastinal Disorders				
Cough ^a	0 (0.0)	2 (10.0)	0 (0.0)	2 (2.6)
Vascular Disorders				
Hypertension ^b	3 (17.6)	0 (0.0)	0 (0.0)	3 (3.8)

^aincludes preferred terms Cough and Productive Cough

^bincludes preferred terms Hypertension and Accelerated Hypertension.

In Studies C08-002A/B, C08-003A/B and C10-004 combined, 60% (47/78) of patients experienced a serious adverse event (SAE).

The following ADRs occurred in >1% to <10% of adult and adolescent patients enrolled in Studies C08-002A/B, C08-003A/B and C10-004.

Table 3: Per Patient Incidence of Adverse Drug Reactions in >1% and <10% Adult and Adolescent Patients Enrolled in aHUS studies C08-002A/B, C08-003A/B and C10-004, Separately and in Total

MedDRA SOC	Number (%) of Patients			
	C08-002 (n=17)	C08-003 (n=20)	C10-004 (n=41)	Total (n=78)
Blood and Lymphatic System Disorders				
Abnormal clotting factor	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Anaemia	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Neutropenia	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Cardiac Disorders				
Cardiomyopathy	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Ear and Labyrinth Disorders				
Deafness bilateral	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Vertigo	1 (5.9)	0 (0.0)	0 (0.0)	1 (1.3)
Eye Disorders				
Lacrimation increased	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Gastrointestinal Disorders				
Abdominal pain	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Diarrhoea	1 (5.9)	0 (0.0)	1 (2.4)	2 (2.6)
Stomatitis	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
General Disorders and Administration Site Conditions				
Asthenia	1 (5.9)	0 (0.0)	2 (4.9)	3 (3.8)

NEW ZEALAND DATA SHEET

MedDRA SOC	Number (%) of Patients			
	C08-002 (n=17)	C08-003 (n=20)	C10-004 (n=41)	Total (n=78)
Chest discomfort	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Extravasation	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Fatigue	1 (5.9)	0 (0.0)	0 (0.0)	1 (1.3)
Pyrexia	1 (5.9)	0 (0.0)	0 (0.0)	1 (1.3)
Infections and Infestations				
Asymptomatic bacteriuria	1 (5.9)	0 (0.0)	0 (0.0)	1 (1.3)
Bacterial infection	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
BK virus infection	0 (0.0)	1 (5.0)	1 (2.4)	2 (2.6)
Herpes zoster	1 (5.9)	0 (0.0)	1 (2.4)	2 (2.6)
Impetigo	1 (5.9)	0 (0.0)	0 (0.0)	1 (1.3)
Influenza	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Meningitis meningococcal	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Meningococcal sepsis	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Nasopharyngitis	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Peritonitis	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Pneumonia	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Pyelonephritis	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Q fever	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Urinary tract infection	1 (5.9)	0 (0.0)	1 (2.4)	2 (2.6)
Investigations				
Haematocrit decreased	1 (5.9)	0 (0.0)	0 (0.0)	1 (1.3)
Haemoglobin decreased	1 (5.9)	0 (0.0)	0 (0.0)	1 (1.3)
Metabolism and nutrition disorders				
Decreased appetite	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Musculoskeletal and Connective Tissue Disorders				
Arthralgia	0 (0.0)	0 (0.0)	2 (4.9)	2 (2.6)
Pain in extremity	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Nervous System Disorders				
Paraesthesia	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Tremor	1 (5.9)	0 (0.0)	0 (0.0)	1 (1.3)
Renal and urinary Disorders				
Haematuria	1 (5.9)	0 (0.0)	0 (0.0)	1 (1.3)
Reproductive system and Breast Disorders				
Menorrhagia	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Respiratory, Thoracic and Mediastinal Disorders				
Dyspnoea	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Dyspnoea exertional	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Nasal congestion	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Oropharyngeal pain	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Rhinorrhoea	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Skin and subcutaneous tissue Disorders				
Alopecia	0 (0.0)	1 (5.0)	2 (4.9)	3 (3.8)
Dermatitis	1 (5.9)	0 (0.0)	0 (0.0)	1 (1.3)
Erythema	1 (5.9)	0 (0.0)	0 (0.0)	1 (1.3)
Photosensitivity reaction	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)
Pruritus	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Rash ^a	0 (0.0)	0 (0.0)	2 (4.9)	2 (2.6)
Skin discolouration	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)

NEW ZEALAND DATA SHEET

MedDRA SOC	Number (%) of Patients			
	C08-002 (n=17)	C08-003 (n=20)	C10-004 (n=41)	Total (n=78)
Vascular Disorders				
Hypotension	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Vein disorder	0 (0.0)	1 (5.0)	0 (0.0)	1 (1.3)
Venous thrombosis	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.3)

^aIncludes rash and rash papular

Paediatric Patients

The following ADRs were reported >10% in the paediatric aHUS Study C10-003:

- 3 (16.8%) respiratory tract infection viral (includes preferred terms: respiratory tract infection viral, viral upper respiratory tract infection and respiratory syncytial virus infection) in 1 month to <12 yrs patients
- 2 (11.8%) rash in 1 month to <12 yrs patients

Table 4 below summarises the adverse events reported in >1% to <10% of paediatric patients enrolled in aHUS Study C10-003.

Table 4: Per Patient Incidence of Adverse Drug Reactions in >1% to <10% of Paediatric Patients Enrolled in aHUS C10-003

MedDRA SOC	Number (%) of Patients	
	1 month to <12 yrs (n=18)	Total (n=22)
Eye Disorders		
Eye discharge	1 (5.6%)	1 (4.5%)
Gastrointestinal Disorders		
Abdominal discomfort	1 (5.6%)	1 (4.5%)
Diarrhoea	1 (5.6%)	1 (4.5%)
Dyspepsia	0 (0.0)	1 (4.5%)
General Disorders and Administration Site Conditions		
Injection site rash	1 (5.6%)	1 (4.5%)
Pain	1 (5.6%)	1 (4.5%)
Infections and Infestations		
Ear infection	1 (5.6%)	1 (4.5%)
Fungal infection	1 (5.6%)	1 (4.5%)
Nasopharyngitis	1 (5.6%)	1 (4.5%)
Respiratory syncytial virus infection	1 (5.6%)	1 (4.5%)
Respiratory tract infection viral	1 (5.6%)	1 (4.5%)
Viral upper respiratory tract infection	1 (5.6%)	1 (4.5%)
Nervous System Disorders		
Headache	1 (5.6%)	1 (4.5%)
Psychiatric Disorders		
Agitation	1 (5.6%)	1 (4.5%)
Skin and Subcutaneous Tissue Disorders		
Alopecia	1 (5.6%)	1 (4.5%)
Dermatitis diaper	1 (5.6%)	1 (4.5%)
Eczema	1 (5.6%)	1 (4.5%)

NEW ZEALAND DATA SHEET

Analysis of retrospectively collected adverse event data from paediatric and adult patients enrolled in aHUS C09-001r revealed a safety profile that was similar to that which was observed in the prospective studies. C09-001r included 19 paediatric patients less than 18 years of age.

Overall, the safety of Soliris in paediatric patients with aHUS enrolled in C09-001r appeared similar to that observed in adult patients. The most common ($\geq 15\%$) Adverse Drug Reactions occurring in paediatric patients are presented in Table 5.

Table 5: Adverse Drug Reactions Occurring in $\geq 15\%$ of Patients <18 Years of Age Enrolled in aHUS Study C09-001r

MedDRA SOC	Number (%) of Patients			
	<2 yrs (n=5)	2 to <12 yrs (n=10)	12 to <18 yrs (n=4)	Total (n=19)
General Disorders and Administration Site Conditions				
Pyrexia	4 (80)	4 (40)	1 (25)	9 (47)
Gastrointestinal Disorders				
Diarrhoea	1 (20)	4 (40)	1 (25)	6 (32)
Vomiting	2 (40)	1 (10)	1 (25)	4 (21)
Infections and Infestations				
Upper respiratory tract infection ^a	2 (40)	3 (30)	1 (25)	6 (32)
Respiratory, Thoracic and Mediastinal Disorders				
Cough	3 (60)	2 (20)	0 (0)	5 (26)
Nasal congestion	2 (40)	2 (20)	0 (0)	4 (21)
Cardiac Disorders				
Tachycardia	2 (40)	2 (20)	0 (0)	4 (21)

^aincludes the preferred terms upper respiratory tract infection and nasopharyngitis.

Tabulated Summary of Adverse Reactions (Including Post-Marketing Experience)

Table 6 below summarises the adverse reactions observed from spontaneous reporting and in completed Soliris clinical trials. The most common adverse reaction was headache (occurring mostly in the initial phase), and the most serious adverse reaction was meningococcal sepsis.

Adverse reactions reported at a very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$) or very uncommon ($< 1/1000$) frequency with Soliris are listed by system organ class and preferred term. Adverse reactions were mostly mild to moderate in severity.

Table 6: Adverse Reactions Reported in Completed Soliris Clinical Trials and in Post Marketing Reports

MedDRA SOC	Very Common ($\geq 1/10$)	Common ($\geq 1/100$ to $< 1/10$)	Uncommon ($\geq 1/1,000$ to $< 1/100$)	Very Uncommon ($< 1/1,000$)
Infection and infestations		Pneumonia, Bronchitis, Upper respiratory tract infection, Nasopharyngitis,	Meningococcal infection ^a , Sepsis, Septic shock, Peritonitis, Lower respiratory tract	Aspergillus infection ^c , Arthritis bacterial ^c , <i>Haemophilus</i>

NEW ZEALAND DATA SHEET

MedDRA SOC	Very Common (≥ 1/10)	Common (≥ 1/100 to < 1/10)	Uncommon (≥ 1/1,000 to < 1/100)	Very Uncommon (<1/1,000)
		Oral Herpes, Urinary tract infection,	infection, Fungal infection, Viral infection, Abscess ^b , Cellulitis, Influenza, Gastrointestinal infection, Cystitis, Infection, Sinusitis, Gingivitis	infection, Genitourinary tract gonococcal infection, Impetigo,
Neoplasms benign, malignant and unspecified				Malignant melanoma, Myelodysplastic syndrome
Blood and lymphatic system disorders		Leucopaenia, Anaemia,	Thrombocytopenia, Lymphopaenia	Haemolysis*, Coagulopathy, Red blood cell agglutination, Abnormal clotting factor
Immune system disorders			Anaphylactic reaction, Hypersensitivity	
Endocrine disorders				Basedow's disease
Metabolism and nutrition disorders			Decreased appetite	
Psychiatric disorders		Insomnia	Depression, Anxiety, Mood swings, Sleep disorder	Abnormal dreams
Nervous system disorders	Headache	Dizziness	Paraesthesia, Tremor, Dysgeusia, Syncope	
Eye disorders			Vision blurred	Conjunctival irritation
Ear and labyrinth disorders			Tinnitus, Vertigo	
Cardiac disorders			Palpitation	
Vascular disorders		Hypertension,	Accelerated hypertension, Hypotension, Hot flush, Vein disorder	Haematoma
Respiratory, thoracic and		Cough, Oropharyngeal pain	Dyspnoea, Epistaxis, Throat irritation,	

NEW ZEALAND DATA SHEET

MedDRA SOC	Very Common (≥ 1/10)	Common (≥ 1/100 to < 1/10)	Uncommon (≥ 1/1,000 to < 1/100)	Very Uncommon (<1/1,000)
mediastinal disorders			Nasal congestion, Rhinorrhoea	
Gastrointestinal disorders		Diarrhoea, Vomiting, Nausea, Abdominal pain	Constipation, Dyspepsia, Abdominal distension	Gastroesophageal reflux disease, Gingival pain
Hepatobiliary disorders				Jaundice
Skin and subcutaneous tissue disorders		Rash, Alopecia, Pruritus	Urticaria, Erythema, Petechiae, Hyperhidrosis, Dry skin, Dermatitis	Skin depigmentation
Musculoskeletal and connective tissue disorders		Arthralgia, Myalgia, Pain in extremity	Muscle spasms, Bone pain, Back pain, Neck pain	Trismus, Joint swelling
Renal and urinary disorders			Renal impairment, Dysuria, Haematuria	
Reproductive system and breast disorders			Spontaneous penile erection	Menstrual disorder
General disorders and administration site condition		Pyrexia, Fatigue, Influenza-like illness	Oedema, Chest discomfort, Asthenia, Chest pain, Infusion site pain, Chills	Infusion site paraesthesia, Extravasation, Feeling hot
Investigations			Alanine aminotransferase increased, Aspartate aminotransferase increased, Gamma-glutamyltransferase increased, Haematocrit decreased, Haemoglobin decreased	Coombs test positive ^c
Injury, poisoning and procedural complication		Infusion related reaction		

**see below "Description of Selected Adverse Reactions"*

^aMeningococcal infection includes the following group of preferred terms: Meningococcal infection, Meningococcal sepsis, Meningococcal meningitis, Neisseria infection

NEW ZEALAND DATA SHEET

^b Abscess includes the following group of preferred terms: Abscess limb, Colonic abscess, Renal abscess, Subcutaneous abscess, Tooth abscess, Hepatosplenic abscess, Perirectal abscess, Rectal abscess

^c ADRs identified in post-marketing reports

Description of Selected Adverse Reactions

In all Soliris clinical studies, the most serious adverse reaction was meningococcal infection. Meningococcal infections in patients treated with Soliris have presented as meningococcal sepsis. Patients should be informed of the signs and symptoms of meningococcal infection and sepsis and advised to seek medical care immediately (see section 4.4 Special Warnings and Precautions for Use).

Other cases of *Neisseria* species have been reported including sepsis with *Neisseria gonorrhoeae*, *Neisseria sicca/subflava*, *Neisseria spp* unspecified.

Cases of haemolysis have been reported in the setting of missed or delayed Soliris dose in PNH clinical trials (see also section 4.4 Special Warnings and Precautions for Use).

Cases of thrombotic microangiopathy complications have been reported in the setting of missed or delayed Soliris dose in aHUS clinical trials (see also Section 4.4 – Special Warnings and Precautions for Use).

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions
<https://nzphvc.otago.ac.nz/reporting/>

4.9 Overdose

No case of overdose has been reported during clinical studies. Supportive and symptomatic care should be provided in the event of overdose.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764 766) in New Zealand or the Poison Information Centre on 13 11 26 (in Australia).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: Selective immunosuppressants, ATC code: L04AA25

Eculizumab is a genetically-engineered humanised monoclonal antibody directed against the α -chain of the C5 complement protein. The antibody is a glycosylated hybrid IgG2-IgG4 kappa immunoglobulin containing human light- and heavy-chain variable region framework sequences, murine complementarity-determining region sequences, and human constant region sequences. Eculizumab is composed of two identical 448 amino acid heavy chains and two identical 214 amino acid light chains, and has a molecular weight of approximately 148 kDa.

The eculizumab antibody is produced by murine myeloma cell culture and purified by standard bioprocess chromatographic technology, including specific viral inactivation and filtration steps.

NEW ZEALAND DATA SHEET

Mechanism of Action

An acquired genetic mutation in patients with Paroxysmal Nocturnal Haemoglobinuria (PNH) leads to the generation of populations of abnormal red blood cells (known as PNH RBCs) that are deficient in complement inhibitors, rendering PNH RBCs sensitive to persistent terminal complement-mediated destruction. The subsequent intravascular haemolysis is the primary disease manifestation in patients with PNH. The destruction and loss of these PNH cells result in low blood counts (anaemia), and also fatigue, difficulty in functioning, pain, dark urine and kidney disease, shortness of breath, and blood clots.

In atypical Haemolytic Uraemic Syndrome (aHUS) impairment of the regulation of the complement activity leads to uncontrolled terminal complement activation, resulting in platelet activation, endothelial cell damage and thrombotic microangiopathy. In patients with aHUS, uncontrolled terminal complement activation and the resulting complement mediated thrombotic microangiopathy are blocked with Soliris treatment.

Eculizumab, the active ingredient in Soliris, is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the membrane attack complex (MAC) C5b-9. Eculizumab preserves the early (proximal) components of complement activation that are essential for opsonisation of microorganisms and clearance of immune complexes.

In Vitro Binding Specificity: The specificity of Soliris for C5 in human serum was evaluated in two *in vitro* studies. The species specificity of Soliris was assessed by determining its ability to inhibit haemolytic activity in non-human sera (4 primate and 4 non-primate species) using a complement-mediated haemolytic assay. The results of this study demonstrate that Soliris does not inhibit C5 activity in sera from the species tested.

The tissue cross-reactivity of Soliris was evaluated by assessing binding to a panel of 38 human tissues. C5 expression in the human tissue panel examined in this study is consistent with published reports of C5 expression, as C5 has been reported in smooth muscle, striated muscle, and renal proximal tubular epithelium. No unexpected tissue cross-reactivity was observed.

Pharmacodynamic Effects

The pharmacodynamic profile of Soliris was assessed using an *in vitro* serum complement haemolysis assay that measures the extent of terminal complement inhibition in the serum of patients receiving Soliris.

In patients with PNH, uncontrolled terminal complement activation and the resulting complement-mediated intravascular haemolysis are blocked with Soliris treatment. Administration of Soliris in an initial phase/maintenance regimen of 600 mg/week for the first 4 weeks and 900 mg in the fifth week of the initial phase, followed by a 900 mg maintenance dose every other week resulted in a rapid and sustained reduction in complement-mediated haemolytic activity. Soliris when administered as recommended provides a blood concentration sufficient to completely block haemolysis within 60 minutes; red blood cell destruction, as indicated by lactate dehydrogenase (LDH) levels, is significantly reduced by one week. In the Phase III study in patients with PNH, C04-001, the dosing regimen was sufficient to maintain plasma Soliris levels to essentially completely block terminal complement activation in 39/40 patients measured for the entire 26 week study period demonstrating that the proposed dosing regimen is adequate.

NEW ZEALAND DATA SHEET

In most patients with PNH, eculizumab serum concentrations of approximately ≥ 35 $\mu\text{g/mL}$ are sufficient for essentially complete inhibition of terminal complement-mediated intravascular haemolysis.

In PNH, chronic administration of Soliris resulted in a rapid and sustained reduction in complement-mediated haemolytic activity.

All patients treated with Soliris as recommended, demonstrated rapid and sustained reduction in terminal complement activity. In all patients with aHUS, eculizumab serum concentrations of approximately 50-100 $\mu\text{g/mL}$ are sufficient for essentially complete inhibition of terminal complement activity.

In aHUS, chronic administration of Soliris resulted in a rapid and sustained reduction in complement mediated thrombotic microangiopathy.

Clinical Trials

Paroxysmal Nocturnal Haemoglobinuria (PNH)

The safety and efficacy of Soliris in patients with PNH with haemolysis were assessed in a randomised, double-blind, placebo-controlled 26-week study (C04-001); patients with PNH were also treated with Soliris in a single arm 52-week study (C04-002); and in a long-term extension study (E05-001). An observational non-interventional Registry for patients with PNH (M07-001) was also initiated to characterise the natural history of PNH in untreated patients and the clinical outcomes during Soliris treatment.

Patients received meningococcal vaccination prior to receipt of Soliris. In all studies, the dose of Soliris was 600 mg every 7 ± 2 days for 4 weeks, followed by 900 mg 7 ± 2 days later, then 900 mg every 14 ± 2 days for the study duration. Soliris was administered as an intravenous infusion over 25 - 45 minutes.

C04-001 Study (TRIUMPH)

Patients with PNH with at least 4 transfusions in the prior 12 months, flow cytometric confirmation of at least 10% PNH type III red blood cells and platelet counts of at least $100 \times 10^9/\text{L}$ were randomised to either Soliris ($n = 43$) or placebo ($n = 44$). Prior to randomisation, all patients underwent an initial observation period to confirm the need for RBC transfusion and to identify the haemoglobin concentration (the "set-point") which would define each patient's haemoglobin stabilisation and transfusion outcomes. The haemoglobin set-point was less than or equal to 90 g/L in patients with symptoms and was less than or equal to 70 g/L in patients without symptoms. Endpoints related to haemolysis included the numbers of patients achieving haemoglobin stabilisation, the number of RBC units transfused, fatigue, and health-related quality of life. To achieve a designation of haemoglobin stabilisation, a patient had to maintain a haemoglobin concentration above the haemoglobin set-point and avoid any RBC transfusion for the entire 26-week period. Haemolysis was monitored mainly by the measurement of serum LDH levels, and the proportion of PNH RBCs was monitored by flow cytometry. Patients receiving anticoagulants and systemic corticosteroids at baseline continued these medications. Major baseline characteristics were balanced (see Table 3). Because of the study sample size and duration, the effects of Soliris on thrombotic events could not be determined.

NEW ZEALAND DATA SHEET

C04-002 Study (SHEPHERD)

Patients with PNH with at least one transfusion in the prior 24 months and platelet counts of at least $30 \times 10^9/L$ received Soliris over a 52-week period. Concomitant medications included anti-thrombotic agents in 63% of the patients and systemic corticosteroids in 40% of the patients. Baseline characteristics are shown in Table 7.

Table 7: Patient Demographics and Characteristics in C04-001 and C04-002 Studies

Parameter	C04-001 Study		C04-002 Study
	Placebo N = 44	Soliris N = 43	Soliris N = 97
Mean Age (SD)	38.4 (13.4)	42.1 (15.5)	41.1 (14.4)
Gender - Female (%)	29 (65.9)	23 (53.5)	49 (50.5)
History of Aplastic Anaemia or MDS (%)	12 (27.3)	8 (18.7)	29 (29.9)
Patients with history of thrombosis (events)	8 (11)	9 (16)	42 (91)
Concomitant Anticoagulants (%)	20 (45.5)	24 (55.8)	59 (61)
Concomitant Steroids/Immunosuppressant Treatments (%)	16 (36.4)	14 (32.6)	46 (47.4)
Discontinued treatment	10	2	1
Packed Red Blood Cells (PRBC) in previous 12 months [median (Q1, Q3)]	17.0 (13.5, 25.0)	18.0 (12.0, 24.0)	8.0 (4.0, 24.0)
Mean Hgb level (g/dL) at set-point (SD)	7.7 (0.75)	7.8 (0.79)	N/A
Pre-treatment LDH levels (median,U/L)	2,234.5	2,032.0	2,051.0
Free Haemoglobin at baseline (median, mg/dL)	46.2	40.5	34.9

In TRIUMPH, patients treated with Soliris had significantly reduced ($p < 0.001$) haemolysis resulting in improvements in anaemia as indicated by increased haemoglobin stabilisation and reduced need for RBC transfusions compared to placebo treated patients (see Table 8). These effects were seen among patients within each of the three pre-study RBC transfusion strata (4 - 14 units; 15 - 25 units; > 25 units). After 3 weeks of Soliris treatment, patients reported less fatigue and improved health-related quality of life.

In SHEPHERD, 96 of the 97 enrolled patients completed the study (one patient died following a thrombotic event). A reduction in intravascular haemolysis as measured by serum LDH levels was sustained for the treatment period and resulted in increased transfusion avoidance, a reduced need for RBC transfusion and less fatigue. See Table 8.

Table 8: Efficacy Outcomes in C04-001 and C04-002

	C04-001 Study			C04-002 Study	
	Placebo N = 44	Soliris N = 43	P - Value	Soliris N = 97	P - Value
Percentage of patients with stabilised Haemoglobin levels at end of study	0	49	< 0.001	N/A	

NEW ZEALAND DATA SHEET

PRBC transfused during treatment (median)	10	0	< 0.001	0.0	< 0.001
Transfusion Avoidance during treatment (%)	0	51	< 0.001	51 ¹	< 0.001
				51 ²	< 0.001
LDH levels at end of study (median, U/L)	2,167	239	< 0.001	269	< 0.001
LDH Area under the curve (AUC) at end of study (median, U/L x Day)	411,822	58,587	< 0.001	-632,264	< 0.001
Free Haemoglobin at end of study (median, mg/dL)	62	5	< 0.001	5	< 0.001
FACIT-Fatigue (effect size) after 6 months treatment	1.13		<0.001	1.01 ¹	< 0.001
FACIT-Fatigue (effect size) after 12 months treatment	N/A			1.14 ²	< 0.001

¹Assessed after 26-week treatment in C04-002.

²Assessed at C04-002 study completion (52 weeks).

E05-001 Study

From the 195 patients that originated in C04-001, C04-002, or C02-001, 187 Soliris-treated patients with PNH were enrolled in a long-term extension study (E05-001). All patients sustained a reduction in intravascular haemolysis over a total Soliris exposure time ranging from 10 to 54 months. Across all enrolled patients with PNH, the thrombosis rate was significantly reduced with Soliris treatment as compared to the thrombosis rate prior to commencement of Soliris treatment. However, the majority of patients received concomitant anticoagulants; the effects of anticoagulant withdrawal during Soliris therapy were not studied. See Table 9.

Table 9: Thromboembolic Event Efficacy Outcomes

	E05-001 (All studies combined)
Pre-Treatment	
Patients (n)	195
Thromboembolic Events (n)	124
Patient Years (n)	1683.4
Thromboembolic Event Rate (n per 100 patient years)	7.37
Soliris Treatment	
Patients (n)	195
Thromboembolic Events (n)	3
Patient Years (n)	281.0
Thromboembolic Event Rate (n per 100 patient years)	1.07 (P<0.001)

M07-001 (PNH Registry)

The PNH Registry (M07-001) was used to evaluate the efficacy of Soliris in patients with PNH with no history of RBC transfusion and a high disease activity, as defined by elevated haemolysis (LDH $\geq 1.5 \times$ ULN) and the presence of related clinical symptom(s): fatigue, haemoglobinuria, abdominal pain, shortness of breath (dyspnoea), anaemia (haemoglobin <100 g/L), major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction.

Patients treated with Soliris were observed to have a reduction in haemolysis and associated symptoms. At 6 months, patients with no history of RBC transfusion treated with Soliris had

NEW ZEALAND DATA SHEET

significantly ($p < 0.001$) reduced LDH levels (median LDH of 305 U/L; Table 10). Furthermore, 74% of the patients treated with Soliris experienced clinically meaningful improvements in FACIT-Fatigue score (i.e., increase by 4 points or more) and 84% in EORTC fatigue score (i.e., decrease by 10 points or more).

Table 10: Efficacy Outcomes (LDH level and FACIT-Fatigue) in Patients with PNH with No History of Transfusion in M07-001

Parameter	Soliris No transfusion
LDH level at baseline (U/L)	n=43 1447
LDH level at 6 months (U/L)	n=36 305
FACIT-Fatigue score at baseline	n=25 32
FACIT-Fatigue score at last available assessment	n=31 44

FACIT-Fatigue is measured on a scale of 0-52, with higher values indicating less fatigue

Atypical Haemolytic Uraemic Syndrome (aHUS)

Data from 100 patients in four prospective controlled studies [3 in adult patients (*C08-002A/B*, *C08-003A/B* and *C10-004*) and 1 in paediatric patients (*C10-003*)] and one retrospective study with 30 patients (*C09-001r*) were used to evaluate the efficacy of Soliris in the treatment of aHUS.

C08-002A/B and *C08-003A/B*

Study C08-002A/B was a prospective, single arm, open-label study which accrued patients in the early phase of aHUS with evidence of clinical thrombotic microangiopathy manifestations with platelet count $\leq 150 \times 10^9/L$ despite Plasma Exchange/Plasma Infusion (PE/PI) and LDH and serum creatinine above upper limits of normal. *Study C08-003A/B* was a prospective, single arm, open-label study which accrued patients with longer term aHUS without apparent evidence of clinical thrombotic microangiopathy manifestations and receiving chronic PE/PI (≥ 1 PE/PI treatment every two weeks and no more than 3 PE/PI treatments/week for at least 8 weeks before the first dose). Patients in both prospective studies were treated with Soliris for 26 weeks and most patients enrolled into a long-term, open-label extension study. All patients enrolled in both prospective studies had an ADAMTS-13 level above 5%.

Patients received meningococcal vaccination prior to receipt of Soliris or received prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination. In all studies, the dose of Soliris in adult and adolescent aHUS patients was 900 mg every 7 ± 2 days for 4 weeks, followed by 1200 mg 7 ± 2 days later, then 1200 mg every 14 ± 2 days for the study duration. Soliris was administered as an intravenous infusion over 35 minutes. The dosing regimen in paediatric patients and adolescents weighing less than 40 kg was defined based on a pharmacokinetic simulation that identified the recommended dose and schedule based on body weight.

Primary endpoints included platelet count change from baseline in *Study C08-002A/B* and thrombotic microangiopathy (TMA) event-free status in *Study C08-003A/B*. Additional endpoints included TMA intervention rate, haematologic normalisation, complete TMA response, changes in LDH, renal function and quality of life. TMA-event free status was defined as the absence for at least 12 weeks of the following: decrease in platelet count of $>25\%$ from baseline, PE/PI, and new dialysis. TMA interventions were defined as PE/PI or new dialysis.

NEW ZEALAND DATA SHEET

Haematologic normalisation was defined as normalisation of platelet counts and LDH levels sustained for ≥ 2 consecutive measurements for ≥ 4 weeks. Complete TMA response was defined as haematologic normalisation and a $\geq 25\%$ reduction in serum creatinine sustained in ≥ 2 consecutive measurements for ≥ 4 weeks. Baseline characteristics are shown in Table 11.

Table 11: Patient Demographics and Characteristics in C08-002A/B and C08-003A/B

Parameter	C08-002A/B	C08-003A/B
	Soliris N = 17	Soliris N = 20
Time from first diagnosis until screening in months, median (min, max)	10 (0.26, 236)	48 (0.66, 286)
Time from current clinical TMA manifestation until screening in months, median (min, max)	<1 (<1, 4)	9 (1, 45)
Number of PE/PI sessions for current clinical TMA manifestation, median (min, max)	17 (2, 37)	62 (20, 230)
Number of PE/PI sessions in 7 days prior to first dose of eculizumab median (min, max)	6 (0, 7)	2 (1, 3)
Baseline platelet count ($\times 10^9/L$), mean (SD)	109 (32)	228 (78)
Baseline LDH (U/L), mean (SD)	323 (138)	223 (70)
Patients without identified mutation, n (%)	4 (24)	6 (30)

Patients in *Study C08-002A/B* received Soliris for a minimum of 26 weeks. After completion of the initial 26-week treatment period, most patients continued to receive Soliris by enrolling into an extension study. The median duration of Soliris therapy in *Study C08-002A/B* was approximately 100 weeks (range: 2 to 186 weeks).

A reduction in terminal complement activity and an increase in platelet count relative to baseline were observed after commencement of Soliris. Reduction in terminal complement activity was observed in all patients after commencement of Soliris.

Table 12 below summarises the efficacy results for *Study C08-002A/B*. All rates of efficacy endpoints improved or were maintained through 2 years of treatment. Complete TMA response was maintained by all responders. When treatment was continued for more than 26 weeks, 2 additional patients achieved and maintained Complete TMA response due to normalisation of LDH (1 patient) and a decrease in serum creatinine (2 patients). Renal function, as measured by eGFR, was improved during Soliris treatment. Four out of the 5 patients who required dialysis at study entry were able to discontinue dialysis for the duration of Soliris treatment, and one patient developed a new dialysis requirement. Patients reported improved health-related quality of life (QOL).

Patients in *Study C08-003A/B* received Soliris for a minimum of 26 weeks. After completion of the initial 26-week treatment period, most patients continued to receive Soliris by enrolling into an extension study. The median duration of Soliris therapy in *Study C08-003A/B* was approximately 156 weeks (range: 26 to 182 weeks). Reduction in terminal complement activity was observed in all patients after commencement of Soliris.

NEW ZEALAND DATA SHEET

Table 12 below summarises the efficacy results for *Study C08-003A/B*. All rates of efficacy endpoints improved or were maintained through 2 years of treatment. Complete TMA response was maintained by all responders. When treatment was continued for more than 26 weeks, 6 additional patients achieved and maintained Complete TMA response due to a decrease in serum creatinine. No patients required new dialysis with Soliris. Renal function, as measured by median eGFR, increased during Soliris therapy.

In both *Study C08-002A/B* and *Study C08-003A/B*, responses to Soliris were similar in patients with and without identified mutations in genes encoding complement regulatory factor proteins.

Table 12: Efficacy Outcomes in Prospective aHUS Studies C08-002A/B and C08-003A/B

	C08-002A/B N = 17		C08-003A/B N = 20	
	At 26 weeks	At 2 years ¹	At 26 weeks	At 2 years ¹
Change in platelet count from baseline through week 26 ($\times 10^9/L$): Point Estimate (95% CI)	73 (40-105) P=0.0001	-	5 (-18, 27) P=0.67	-
Normalisation of platelet count	14 (82) (57,96)	15 (88) (64,99)	18 (90) (68,99)	18 (90) (68,99)
All patients, n (%) (95% CI)	13/15, (87)	13/15, (87)	1/3 (33)	1/3 (33)
Patients with abnormal baseline, n/n (%)				
TMA event-free status: n (%) (95% CI)	15 (88) (64, 99)	15 (88) (64, 99)	16 (80) (56, 94)	19 (95) (75, 99)
TMA intervention rate				
Daily pre-eculizumab rate, median (min, max)	0.88 (0.04, 1.59)	0.88 (0.04,1.59)	0.23 (0.05, 1.09)	0.23 (0.05,1.09)
Daily during-eculizumab rate, median (min, max)	0 (0, 0.31)	0 (0, 0.31)	0	0
P-value	P<0.0001	P<0.0001	P <0.0001	P <0.0001
Chronic Kidney Disease (CKD) improvement by ≥ 1 stage: n (%) (95% CI)	10 (59) (33, 82)	12 (71) (44, 90)	7 (35) (15, 59)	12 (60) (36, 81)
eGFR change mL/min/1.73 m ² : median (range)	20 (-1,98)	28 (3, 82)	5 (-1, 20)	11 (-42, 30)
eGFR improvement ≥ 15 mL / min / 1.73 m ² : n (%) (95% CI)	8 (47) (23, 72)	10 (59) (33, 82)	1 (5) (0, 25)	8 (40) (19, 64)
Change in Hgb > 20g/L: n (%) (95% CI)	11 (65) (38, 86) ²	13 (76) (50, 93)	9 (45) (23, 68) ³	13 (65) (41, 85)
Haematologic normalisation: n (%) (95% CI)	13 (76) (50, 93)	15 (88) (64, 99)	18 (90) (68, 99)	18 (90) (68, 99)
Complete TMA response: n (%) (95% CI)	11 (65) (38, 86)	13 (76) (50, 93)	5 (25) (9, 49)	11 (55) (32, 77)

¹At data cut-off (20 April 2012)

²Study C08-002: 3 patients received ESA which was discontinued after eculizumab initiation.

³Study C08-003: 8 patients received ESA which was discontinued in 3 of them during eculizumab therapy.

NEW ZEALAND DATA SHEET

C10-004

Study C10-004 enrolled 41 patients who displayed signs of thrombotic microangiopathy (TMA). In order to qualify for enrolment, patients were required to have a platelet count < lower limit of normal range, evidence of haemolysis such as an elevation in serum LDH, and serum creatinine above the upper limits of normal, without the need for chronic dialysis. The median patient age was 35 (range: 18 to 80 years). All patients enrolled in *Study C10-004* had an ADAMTS-13 level above 5%. Fifty-one percent of patients had an identified complement regulatory factor mutation or auto-antibody. A total of 35 patients received PE/PI prior to Soliris. Table 13 summarises the key baseline clinical and disease-related characteristics of patients enrolled in *Study C10-004*.

Table 13: Baseline Characteristics of Patient Enrolled in Study C10-004

Parameter	Study C10-004 N=41
Time from aHUS diagnosis to first study dose (months), median (min, max)	0.79 (0.03, 311)
Time from current clinical TMA manifestation until first study dose (months), median (min, max)	0.52 (0.03, 19)
Baseline platelet count ($\times 10^9/L$), median (min, max)	125 (16, 332)
Baseline LDH (U/L), median (min, max)	375 (131, 3318)
Baseline eGFR (mL/min/1.73m ²), median (mix, max)	10 (6, 53)

Patients in *Study C10-004* received Soliris for a minimum of 26 weeks. After completion of the initial 26-week treatment period, most patients elected to continue on chronic dosing.

Reduction in terminal complement activity and an increase in platelet count relative to baseline were observed after commencement of Soliris. Soliris reduced signs of complement-mediated TMA activity, as shown by an increase in mean platelet counts from baseline to 26 weeks. In *Study C10-004*, mean platelet count (\pm SD) increased from $119 \pm 66 \times 10^9/L$ at baseline, to $200 \pm 84 \times 10^9/L$ by one week; this effect was maintained through 26 weeks (mean platelet count (\pm SD) at week 26: $252 \pm 70 \times 10^9/L$). Renal function, as measured by eGFR, was improved during Soliris therapy. Twenty of the 24 patients who required dialysis at baseline were able to discontinue dialysis during Soliris treatment. Table 14 summarises the efficacy results for *Study C10-004*.

Table 14: Efficacy Outcomes for Prospective Study C10-004

Efficacy Parameter	Study C10-004 (N = 41) At 26 weeks
Change in platelet count through week 26 ($10^9/L$)	111 (-122, 362)
Haematologic Normalisation, n (%)	36 (88)
Median duration of haematologic normalisation, months (range)	15 (2, 27)
Complete TMA response, n (%)	23 (56)
Median duration of Complete TMA response, months (range)	16 (1, 26)

NEW ZEALAND DATA SHEET

Efficacy Parameter	Study C10-004 (N = 41) At 26 weeks
TMA Event-free Status, n (%) 95% CI	37 (90) 77; 97
Daily TMA Intervention Rate, median (range) Before Soliris treatment On Soliris treatment	0.63 (0, 1.38) 0 (0, 0.59)

Longer term treatment with Soliris (median 52 weeks, ranging from 15 to 126 weeks) was associated with an increased rate of clinically meaningful improvements. When Soliris treatment was continued for more than 26 weeks, 3 additional patients (63% of patients in total) achieved Complete TMA response and 4 additional patients (98% of patients in total) achieved haematologic normalisation. At the last evaluation, 25 of 41 patients (61%) achieved eGFR improvement of ≥ 15 mL/min/1.73 m² from baseline.

Paediatric Population

PNH

M07-005

A total of 7 paediatric patients with PNH, with a median weight of 57.2 kg (range of 48.6 to 69.8 kg) and aged from 11 to 17 years (median age: 15.6 years) received Soliris in *Study M07-005*.

Treatment with Soliris at the paediatric population dosing regimen was associated with a reduction of intravascular haemolysis as measured by serum LDH level. It also resulted in a marked decrease or elimination of blood transfusions, and a trend towards an overall improvement in general function. The efficacy of Soliris treatment in paediatric patients with PNH appears to be consistent with that observed in adult patients with PNH enrolled in PNH pivotal Studies (*C04-001 and C04-002*) (refer to Table 8 above and Table 15 below).

Table 15: Efficacy Outcomes in Paediatric PNH Study *M07-005*

		P - Value	
	Mean (SD)	Wilcoxon Signed Rank	Paired t-test
Change from baseline at 12 weeks of LDH Value (U/L)	-771 (914)	0.0156	0.0336
LDH AUC (U/L x Day)	-60,634 (72,916)	0.0156	0.0350
Change from baseline at 12 weeks in Plasma Free Haemoglobin (mg/dL)	-10.3 (21.13)	0.2188	0.1232
Change from baseline Type III RBC clone size (Percent of aberrant cells)	1.80 (358.1)		
Change from baseline at 12 weeks of PedsQL™4.0 Generic Core scale (children)	10.5 (6.66)	0.1250	0.0256
Change from baseline at 12 weeks of PedsQL™4.0 Generic Core scale (parents)	11.3 (8.5)	0.2500	0.0737
Change from baseline at 12 weeks of PedsQL™ Multidimensional Fatigue (children)	0.8 (21.39)	0.6250	0.4687

NEW ZEALAND DATA SHEET

		P - Value	
	Mean (SD)	Wilcoxon Signed Rank	Paired t-test
Change from baseline at 12 weeks of PedsQL™ Multidimensional Fatigue (parents)	5.5 (0.71)	0.5000	0.0289

Atypical Haemolytic Uraemic Syndrome

C09-001r

A total of 15 paediatric patients (aged 2 months to 12 years) received Soliris in aHUS *Study C09-001r*. Forty seven percent of patients had an identified complement regulatory factor mutation or auto-antibody. The median time from aHUS diagnosis to first dose of Soliris was 14 months (range <1 to 110 months). The median time from current thrombotic microangiopathy manifestation to first dose of Soliris was 1 month (range <1 to 16 months). The median duration of Soliris therapy was 16 weeks (range 4 to 70 weeks) for children under 2 years of age (n=5) and 31 weeks (range 19 to 63 weeks) for children 2 years to < 12 years of age (n=10).

Overall, the efficacy results of these paediatric patients appeared consistent with what was observed in patients enrolled in aHUS pivotal Studies *C08-002 and C08-003* (Table 16). No paediatric patient required new dialysis during treatment with Soliris.

Table 16: Efficacy Results in Paediatric aHUS Study *C09-001r*

Efficacy Parameter	<2 yrs (n = 5)	2 to <12 yrs (n = 10)	12 to <18 yrs (n = 4)	Total (n = 19)
Platelet count normalisation, n (%) ¹	4 (80)	10 (100)	3 (75)	17 (89)
Hematologic Normalisation, n (%)	2 (40)	5 (50)	1 (25)	8 (42)
Complete TMA response, n (%)	2 (40)	5 (50)	1 (25)	8 (42)
Daily TMA intervention rate, median (range)				
Before eculizumab	1 (0, 2)	<1 (0.07, 1.46)	<1 (0, 1)	0.31 (0.00, 2.38)
On eculizumab treatment	<1 (0, <1)	0 (0, <1)	0 (0, <1)	0.00 (0.00, 0.08)
Patients with eGFR improvement ≥ 15 mL/min/1.73 m ² , n (%) ²	2 (40)	6 (60)	1 (25)	9 (47)

¹Platelet count normalisation was defined as a platelet count of at least 150 X 10⁹/L on at least two consecutive measurements spanning a period of at least 4 weeks.

²Of the 9 patients who experienced an eGFR improvement of at least 15 mL/min/1.73 m², one received dialysis throughout the study period, and another received eculizumab as prophylaxis following renal allograft transplantation.

C10-003

NEW ZEALAND DATA SHEET

A total of 22 paediatric and adolescent patients (aged 5 months to 17 years) received Soliris in *Study C10-003*. Patients who enrolled in the study were required to have a platelet count < lower limit of normal range, evidence of haemolysis such as an elevation in serum LDH above the upper limits of normal and serum creatinine level ≥ 97 percentile for age without the need for chronic dialysis. Patients enrolled in *Study C10-003* had an ADAMTS-13 level above 5%. Fifty percent of patients had an identified complement regulatory factor mutation or auto-antibody. A total of 10 patients received PE/PI prior to Soliris. Table 17 below summarises the key baseline clinical and disease-related characteristics of patients enrolled in *Study C10-003*.

Table 17: Baseline Characteristics of Paediatric Patients Enrolled in Study C10-003

Parameter	1 month to <12 years (n=18)	All patients (n=22)
Time from aHUS diagnosis until first study dose (months); median (min, max)	0.51 (0.03, 58)	0.56 (0.03, 191)
Time from current clinical TMA manifestation until first study dose (months); median (min, max)	0.23 (0.03, 4)	0.20 (0.03, 4)
Baseline platelet count ($\times 10^9/L$); median (min, max)	110 (19, 146)	91 (19, 146)
Baseline LDH (U/L); median (min, max)	1510 (282, 7164)	1244 (282, 7164)
Baseline eGFR (mL/min/1.73 m ²), median (min, max)	22 (10, 105)	22 (10, 105)

Patients in *Study C10-003* received Soliris for a minimum of 26 weeks. After completion of the initial 26-week treatment period, most patients elected to continue on chronic dosing. Reduction in terminal complement activity was observed in all patients after commencement of Soliris. Soliris reduced signs of complement-mediated TMA activity, as shown by an increase in mean platelet counts from baseline to 26 weeks.

The mean platelet count (\pm SD) increased from $88 \pm 42 \times 10^9/L$ at baseline, to $281 \pm 123 \times 10^9/L$ by one week; this effect was maintained through 26 weeks (mean platelet count (\pm SD) at week 26: $293 \pm 106 \times 10^9/L$). Renal function, as measured by median eGFR, was improved during Soliris therapy. Nine of the 11 patients who required dialysis at baseline no longer required dialysis after Study Day 15 of Soliris treatment.

Responses were similar across all ages from 5 months to 17 years of age. In *Study C10-003*, responses to Soliris were similar in patients with and without identified mutations in genes encoding complement regulatory factor proteins or auto-antibodies to factor H. Table 18 summarises the efficacy results for *Study C10-003*.

Table 18: Efficacy Outcomes in Prospective aHUS Paediatric Study C10-003

Efficacy Parameter	1 month to <12 years (n=18) At 26 weeks	All patients (n=22) At 26 weeks
Complete haematologic normalisation, n (%)	14 (78)	18 (82)
Median duration of Complete haematologic normalisation, months (range)	13 (7, 26)	14.5 (7, 26)

NEW ZEALAND DATA SHEET

Efficacy Parameter	1 month to <12 years (n=18) At 26 weeks	All patients (n=22) At 26 weeks
Complete TMA response, n (%)	11 (61)	14 (64)
Median duration of Complete TMA response, months (range)	11 (8, 26)	13 (5.5, 26)
TMA Event-Free Status, n (%)	17 (94)	21 (96)
95% CI	NA	77; 99
Daily TMA Intervention rate, median (range)		
Before Soliris treatment, median	NA	0.4 (0, 1.6)
On Soliris treatment, median	NA	0 (0, 0)
eGFR improvement ≥ 15 mL/min/ $1.73 \cdot m^2$, n (%)	16 (89)	19 (86)
Change in eGFR (≥ 15 mL/min/ $1.73 \cdot m^2$) at 26 weeks, median (range)	64 (0, 146)	58 (0, 146)
CKD improvement by ≥ 1 stage, n (%)	14/16 (88)	17/20 (85)
PE/PI Event-Free Status, n (%)	16 (89)	20 (91)
New Dialysis Event-Free Status, n (%)	18 (100)	22 (100)
95% CI	NA	85;100

Longer term treatment with Soliris (median 55 weeks; ranging from 1 day to 107 weeks) was associated with an increased rate of clinically meaningful improvements. When Soliris treatment was continued for more than 26 weeks, 1 additional patient (68% of patients in total) achieved Complete TMA Response and 2 additional patients (91% of patients in total) achieved haematologic normalisation. At the last evaluation, 19 of 22 patients (86%) achieved eGFR improvement of ≥ 15 mL/min/ $1.73 m^2$ from baseline. No patient required new dialysis with Soliris.

5.2 Pharmacokinetic Properties

In patients with PNH, pharmacodynamic activity correlates directly with eculizumab serum concentrations and maintenance of trough levels above ≥ 35 $\mu\text{g/mL}$ results in essentially complete blockade of haemolytic activity in the majority of patients with PNH.

Metabolism

Biotransformation: Human antibodies undergo endocytotic digestion in the cells of the reticuloendothelial system. Eculizumab contains only naturally occurring amino acids and has no known active metabolites. Human antibodies are predominately catabolised by lysosomal enzymes to small peptides and amino acids.

Excretion

Elimination: No specific studies have been performed to evaluate the hepatic, renal, lung, or gastrointestinal routes of excretion/elimination for Soliris. In patients with normal kidneys, antibodies are not excreted and are excluded from filtration by their size.

The pharmacokinetics (PK) of Soliris were studied in patients with PNH using total serum concentrations (free and bound drug). In 40 patients with PNH, a 1-compartmental model was used to estimate PK parameters after the multiple doses. Mean clearance was 0.31 ± 0.12 mL/hr/kg, mean volume of distribution was 110.3 ± 17.9 mL/kg, and mean elimination half-life

NEW ZEALAND DATA SHEET

was 11.3 ± 3.4 days. Based on these data, the onset of steady state is predicted to be approximately 49 – 56 days.

A second population PK analysis with a standard 1 compartmental model was conducted on the multiple dose PK data from 37 aHUS patients receiving the recommended Soliris regimen in studies C08-002A/B and C08-003A/B. In this model, the clearance of Soliris for a typical aHUS patient weighing 70 kg was 0.0139 L/hr and the volume of distribution was 5.6 L. The elimination half-life was 297 h (approximately 12.4 days).

The clearance and half-life of eculizumab were also evaluated during plasma exchange interventions. Plasma exchange resulted in an approximately 50% decline in eculizumab concentrations following a 1 hour intervention and the elimination half-life of eculizumab was reduced to 1.3 hours. Supplemental dosing is recommended when Soliris is administered to aHUS patients receiving plasma infusion or exchange (see section 4.2).

Special Populations:

PNH

Formal studies have not been conducted to evaluate the PK of Soliris administration in special PNH patient populations based on gender, race, age (geriatric).

Paediatric patients: the pharmacokinetics of eculizumab were evaluated in Study *M07-005* including 7 paediatric patients with PNH (aged from 11 to < 18 years). Weight was a significant covariate resulting in lower eculizumab clearance. Dosing for paediatric patients <40 kg is based on paediatric patients with aHUS.

aHUS

The pharmacokinetics of Soliris have been studied in patients with aHUS with a range of renal impairment and age. There have been no observed differences in PK parameters noted in these subpopulations of patients with aHUS.

Paediatric patients: the second population PK model was applied to the multiple dose PK data from 22 paediatric patients with aHUS receiving the recommended Soliris regimen in *Study C10-003*. Clearance values of Soliris in paediatric patients with aHUS were 0.0104 L/h, 0.0053 L/h and 0.0022 L/h with body weight of 70, 30, and 10 kg, respectively; and the corresponding volume of distribution values were 5.23, 2.76, and 1.21 L, respectively. The corresponding elimination half-life remained almost unchanged within a range of 349 to 378h (approximately 14.5 to 15.8 days).

5.3 Preclinical Safety Data

Genotoxicity

No studies have been conducted to assess the genotoxic potential of eculizumab.

Carcinogenicity

No studies have been conducted to assess the carcinogenic potential of eculizumab.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients

monobasic sodium phosphate monohydrate
dibasic sodium phosphate heptahydrate

NEW ZEALAND DATA SHEET

sodium chloride
polysorbate 80 (vegetable origin)
Water for Injection

6.2 Incompatibilities

This medicine must not be mixed with other medicines except those mentioned in section 6.6 Special Precautions for Disposal and other Handling.

6.3 Shelf Life

30 months.

After dilution, the medicinal product should be used immediately. Diluted solutions of Soliris are stable for 24 hours. If a diluted solution has been prepared more than 4 hours prior to administration, it should be stored at 2° to 8°C for not more than 24 hours.

6.4 Special Precautions for Storage

For storage conditions after dilution of the medicine, see section 6.3 Shelf Life.

Soliris vials must be stored in the original carton until time of use under refrigerated conditions at 2° to 8°C and protected from light. Soliris vials in the original package may be removed from refrigerated storage (up to 25°C) for only one single period up to 3 days. At the end of this period unopened product can be put back in the refrigerator.

DO NOT FREEZE. DO NOT SHAKE.

6.5 Nature and Contents of Container

30mL glass vial (Type I).

6.6 Special Precautions for Disposal and other Handling

Soliris contains no preservatives and is for single use in one patient only. Discard any residue. Unused or expired medicine should be returned to a pharmacy for disposal.

Instructions for Use/Handling

Dilution should be performed in accordance with good practice rules, including aseptic conditions. The Soliris admixture should be inspected visually for particulate matter and discolouration prior to administration. The solution should only be used if the solution is clear and free from particles.

Soliris must be diluted to a final admixture concentration of 5 mg/mL using the following steps:

- Withdraw the total amount of Soliris from the vial into a sterile syringe.
- Transfer the recommended dose to an infusion bag.
- Dilute Soliris to a final concentration of 5 mg/mL by adding the appropriate amount (equal volume of diluent to drug volume) of 0.9% Sodium Chloride Injection USP; 0.45% Sodium Chloride Injection USP; 5% Dextrose in Water Injection USP; or Ringer's Solution for Intravenous Infusion USP to the infusion bag.
- Do not mix with other medicinal products

Soliris dose	Diluent volume	Final volume
--------------	----------------	--------------

NEW ZEALAND DATA SHEET

300 mg	30 mL	60 mL
600 mg	60 mL	120 mL
900 mg	90 mL	180 mL
1200 mg	120 mL	240 mL

- Gently invert the infusion bag containing the diluted Soliris solution to ensure thorough mixing of the product and diluent.
- Prior to administration, the admixture should be allowed to reach 18° to 25°C. The admixture must not be heated in a microwave or with any heat source other than ambient air temperature.

7. MEDICINE SCHEDULE

Prescription medicine

8. SPONSOR

Pharmacy Retailing NZ Ltd t/a Healthcare Logistics
58 Richard Pearse Drive
Airport Oaks Auckland 2022
(09) 9185 100

Email: medicalinformation.australasia@alexion.com

9. DATE OF FIRST APPROVAL

1 September 2011

10. DATE OF REVISION OF THE TEXT

30 March 2023

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
4.5	Updated information regarding potential interactions
4.8	Updated frequency information for pre-existing adverse reactions previously documented in the Product Information document. Clarification of wording with respect to meningococcal sepsis/infection